Decision Support in Pennsylvania

Saladax Biomedical, Inc. is a biotechnology company specializing in therapeutic drug monitoring (TDM) assays for psychiatry and oncology. The company develops and manufactures rapid blood-level measurement tests that optimize drug dosing for essential medications prescribed by psychiatrists and oncologists. Key products include the My5-FU Assay for monitoring 5-Fluorouracil chemotherapy (Health Canada approved, May 2024) and MyCare™ Insite for clozapine monitoring with point-of-care testing capabilities, delivering results in hours rather than days. Saladax supports personalized medicine initiatives through companion diagnostics and clinical trial collaborations with pharmaceutical partners. The company's TDM solutions enable clinicians to confirm medication adherence, optimize dosing regimens, and reduce toxicity risks, improving patient outcomes in psychiatric and oncological care. International distribution partnerships expand access across multiple regions.

OK2StandUP Inc. develops an AI-powered wearable patient monitoring system designed to predict and alert clinical staff of a patient's intention to sit up or change position within 6 seconds, supporting fall prevention protocols in hospitals, skilled nursing facilities, rehabilitation centers, and memory care communities. The system employs machine learning algorithms to detect movement patterns associated with sit-up intent, generating real-time notifications to care teams while minimizing false alarms (averaging 0.1 per bed per day). The technology is worn by patients and integrates into existing workflows without requiring cameras or one-on-one sitters, supporting evidence-based fall prevention strategies and reducing unnecessary room checks. Clinical feasibility studies across five nursing homes involving 44 high fall-risk residents over 4,500 monitoring hours reported zero falls during monitoring periods and 95% accuracy in intent detection. The system targets workflow integration for rounding, fall risk assessment, and mobility monitoring protocols. OK2StandUP serves healthcare systems, nursing homes, rehabilitation facilities, and memory care operators seeking non-invasive, AI-augmented patient safety solutions. The company is positioned for partnerships with OEM vendors seeking AI service layers and with clinical leaders implementing comprehensive fall prevention strategies.

Proscia, Inc. is an enterprise digital pathology and AI software platform company serving diagnostic laboratories, academic medical centers, health systems, pharmaceutical companies, contract research organizations (CROs), and biotech firms. The company develops and markets Concentriq, a purpose-built digital pathology platform offered in three modules: Concentriq LS for life sciences R&D and biomarker discovery; Concentriq AP for clinical laboratory digitization and workflow management; and Concentriq AP-Dx, which is FDA-cleared for primary diagnosis and supports both late-stage clinical trials and routine diagnostic operations. Proscia Aperture is a precision medicine analytics solution that converts pathology data into real-time, point-of-diagnosis patient insights for drug development and real-world evidence generation. The platform integrates AI analysis tools for pathologists and scientists, enabling automated image analysis, data harmonization across siloed sources, and collaborative research workflows. The company serves over 12,000 daily users across major diagnostic reference labs, 16 of the top 20 pharmaceutical companies, and leading academic institutions including Cleveland Clinic and PathGroup. Proscia holds FDA clearance for diagnostic applications and is recognized by KLAS as a leader in digital pathology. The company has raised significant capital to advance AI-driven pathology solutions and has been acknowledged by Fast Company and Fierce Biotech for innovation in AI and digital health.

Net Health is a healthcare software provider with 30 years of specialized EHR and analytics expertise. The company develops tailored electronic health record (EHR) systems and electronic medical record (EMR) solutions for wound care, rehabilitation therapy, post-acute care, and occupational health. Net Health's platform serves over 25,000 healthcare facilities and 96% of top US health systems. Core offerings include specialized EHR software with built-in compliance and billing functionality, clinical and operational analytics with predictive models, patient engagement and marketing tools, and interoperable integrations with existing hospital information systems (HIS) and EMRs. Key product lines include WoundExpert (wound care EHR with mobile wound imaging analytics), Tissue Analytics (wound measurement and imaging AI), ReDoc (rehabilitation EHR for hospitals), Optima (EHR for skilled nursing and assisted living), FOTO Analytics (outcome measurement), PointRight (value-based care and SNF analytics), and Agility (occupational health platform). The company emphasizes regulatory compliance, automated documentation, clinical analytics grounded in specialty data, and decision support tools. Net Health's solutions operate across multiple care settings: hospitals, outpatient clinics, private practices, home health, skilled nursing facilities, senior living communities, and traveling physician services. All solutions are cloud-based and designed for interoperability and data-driven clinical decision-making.

Plexision develops cellular biomarkers and diagnostic platforms for personalized medicine in solid organ transplantation and immunological disorders. The company specializes in biomarker discovery and validation, offering diagnostic services and R&D support across transplant rejection, viral infections, COVID-19, immune deficiency, and immuno-oncology applications. Plexision's technology platform enables risk assessment for immunological disorders, drug efficacy prediction for patient populations, and dosing optimization for new immunological therapeutics. The company operates a CLIA-certified laboratory in Pittsburgh, PA, supporting both clinical diagnostics and pharmaceutical drug development across preclinical through post-marketing phases. Services include biomarker integration into drug development pipelines and personalized diagnostic testing.

MindTrace is a Pittsburgh-based AI/ML software platform (Carnegie Mellon University spinoff, founded 2020) designed to support neurosurgical planning and intraoperative decision-making. The platform integrates multiple data sources to enable clinicians to predict cognitive outcomes before, during, and after brain surgery. MindTrace provides structured neurocognitive assessment workflows—measuring language, memory, attention, and other critical functions—allowing surgical teams to iterate on resection strategies while evaluating trade-offs between lesion removal and preservation of healthy brain tissue. The system integrates into clinical, operating room, and epilepsy monitoring workflows, supporting inpatient, perioperative, intraoperative, and telehealth settings. Used across U.S. medical centers under IRB oversight, MindTrace bridges clinical neurocognitive assessment with translational research data collection, enabling reproducible multi-site studies without custom infrastructure. The platform serves neurosurgeons, hospitals, researchers, and patients seeking evidence-based preoperative surgical planning and quantitative projections of postoperative function and quality of life.